Please login to the form below

Not currently logged in
Email:
Password:

baricitinib

This page shows the latest baricitinib news and features for those working in and with pharma, biotech and healthcare.

Cambridge University scientists identify 160 new drugs with COVID-19 repurposing potential

Cambridge University scientists identify 160 new drugs with COVID-19 repurposing potential

In April, the European Medicines Agency (EMA) launched a rolling review of one of these repurposed drugs – Eli Lilly’s rheumatoid arthritis/eczema treatment Olumiant (baricitinib) – as a treatment of

Latest news

More from news
Approximately 10 fully matching, plus 41 partially matching documents found.

Latest Intelligence

  • NICE – but not enough NICE – but not enough

    A great illustration of why this is unfortunately a myth can be seen in Figure 1, which charts the formulary adoption of Olumiant (baricitinib) – Lilly’s once-daily pill for moderate

  • AI: the smart money is on the smart thinking AI: the smart money is on the smart thinking

    Take, for example, the case of baricitinib, originally an Eli Lilly rheumatoid arthritis drug, now repurposed as a promising treatment for COVID-19.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Lilly’s already-approved Olumiant (baricitinib) and Pfizer’s PF-04965842 are rivals for Abbvie’s upadacitinib, but Gilead and Galapagos’ filgotinib (an AbbVie cast-off) now looks like the biggest

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...